History of Changes for Study: NCT00637377

NIH U.S. National Library of Medicine

ClinicalTrials.gov archive

History of Changes for Study: NCT00637377

VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2).

Latest version (submitted November 28, 2014) on ClinicalTrials.gov

- A study version is represented by a row in the table.
- · Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-l
 applies to the Protocol section of the study.
- · Click "Compare" to do the comparison and show the differences.
- · Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study versio
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in red.
- Study additions are displayed in green.

Study Record Versions

Version	Α	В	Submitted Date	Changes
1	\bigcirc		March 17, 2008	None (earliest Version on record)
2	\bigcirc	\bigcirc	<u> April 24, 2008</u>	Recruitment Status, Contacts/Locations, Study Status and Oversight
3	\bigcirc	\bigcirc	<u>June 19, 2008</u>	Contacts/Locations and Study Status

https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop

DOCKET

LARM

Α

History of Changes for Study: NCT00637377

Version	Α	В	Submitted Date	Changes
4	\bigcirc	\bigcirc	<u>August 4, 2008</u>	Contacts/Locations, Study Status and Eligibility
5	\bigcirc	\bigcirc	September 30, 2008	Contacts/Locations, Study Status, Sponsor/Collaborators, Eligibility and Study Identification
6	\bigcirc	\bigcirc	<u>October 2, 2008</u>	Contacts/Locations, Study Status and Study Identification
7	\bigcirc	\bigcirc	November 4, 2008	Contacts/Locations, Study Status, Sponsor/Collaborators and Study Identification
8	\bigcirc	\bigcirc	<u>December 1, 2008</u>	Study Status and Contacts/Locations
9	\bigcirc	\bigcirc	<u>January 5, 2009</u>	Contacts/Locations and Study Status
10	\bigcirc	\bigcirc	February 5, 2009	Contacts/Locations and Study Status
11	\bigcirc	\bigcirc	<u>March 5, 2009</u>	Contacts/Locations, Study Status, Eligibility and Sponsor/Collaborators
12	\bigcirc	\bigcirc	<u>April 2, 2009</u>	Contacts/Locations, Study Status and Eligibility
13	\bigcirc	\bigcirc	<u>May 4, 2009</u>	Study Status
14	\bigcirc	\bigcirc	<u>June 4, 2009</u>	Contacts/Locations, Study Status and Eligibility
15	\bigcirc	\bigcirc	<u>July 3, 2009</u>	Contacts/Locations, Study Status and Eligibility
16	\bigcirc	\bigcirc	<u>September 1, 2009</u>	Contacts/Locations, Study Status and Eligibility
17	\bigcirc	\bigcirc	September 23, 2009	Recruitment Status, Contacts/Locations and Study Status
18	\bigcirc	\bigcirc	<u>November 19, 2009</u>	Study Status
19	\bigcirc	\bigcirc	<u>February 19, 2010</u>	Contacts/Locations, Study Status, Arms and Interventions, Study Design and Study Ider
20	0	0	<u>July 9, 2010</u>	Contacts/Locations and Study Status
21	\bigcirc	\bigcirc	<u>October 6, 2010</u>	Study Status

https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop

Δ

R


Μ

Δ

Version	Α	в	Submitted Date	Changes
22	0	0	<u>November 30, 2010</u>	Contacts/Locations, Study Status and Study Design
23	\bigcirc	0	<u>February 21, 2011</u>	Study Status
24	0	0	<u>May 23, 2011</u>	Study Status, Contacts/Locations, Sponsor/Collaborators and Study Identification
25	\bigcirc	\bigcirc	<u>June 6, 2011</u>	Contacts/Locations, Arms and Interventions, Study Status, Study Identification, Outcome Sponsor/Collaborators
26	0	\bigcirc	December 16, 2011	Recruitment Status, Study Status, Outcome Measures, Arms and Interventions, Study Io References, Contacts/Locations, Eligibility and Study Description
27	\bigcirc	\bigcirc	February 27, 2012	Study Status
28	\bigcirc	\bigcirc	March 12, 2013	Reported Adverse Events, Contacts/Locations, Study Status and References
29	\bigcirc	\bigcirc	<u>April 25, 2014</u>	Sponsor/Collaborators, Study Status, Baseline Characteristics and References
30	\bigcirc	\bigcirc	<u>November 28, 2014</u>	Study Status and References
Compare			Comparison Form	at: O Side-by-Side

Scroll up to access the controls

Study NCT00637377 Submitted Date: March 17, 2008 (v1)



History of Changes for Study: NCT00637377

Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovasci Macular Degeneration (AMD). Secondary IDs: EurdaCT No.: 2007-000583-25

311523 VIEW 2

Study Status

Record Verification: March 2008

Overall Status: Not yet recruiting

Study Start: March 2008

Primary Completion:

Study Completion: September 2011 [Anticipated]

First Submitted: March 12, 2008

First Submitted that March 17, 2008 Met QC Criteria:

First Posted: March 18, 2008 [Estimate]

Last Update Submitted that March 17, 2008 Met QC Criteria:

Last Update Posted: March 18, 2008 [Estimate]

Sponsor/Collaborators

Sponsor: Bayer

Responsible Party:

Collaborators: Regeneron Pharmaceuticals

Oversight

ARM

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop

RM

History of Changes for Study: NCT00637377 Data Monitoring: Yes Study Description Brief Summary: This study is a phase III, double-masked, randomized, study of the efficacy and saf Eye in patients with neovascular age-related macular degeneration. Approximately be randomized in Europe, Asia, Japan, Australia and South America. Detailed Description: Conditions Conditions: Macular Degeneration Keywords: Eye diseases Vision Impairment and Blindness Eyes and Vision Seniors Neovascular Age-Related Macular Degeneration (AMD) Retinal Disease Study Design Study Type: Interventional Primary Purpose: Treatment Study Phase: Phase 3 Interventional Study Model: Parallel Assignment Number of Arms: 4 Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Allocation: Randomized Enrollment: 1200 [Anticipated] Arms and Interventions Arms Assigned Interventions

https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.